Can Psychedelics Change the Pharmaceutical Industry?
After years of restrictions, Psychedelic compounds like psilocybin, ketamine and MDMA have been permitted to once again be studied and adapted into potential therapies for a variety of mental illnesses and could spark a revolution in the pharmaceutical industry. Join Mark Noble, Executive Vice President, ETF Strategy at Horizons ETFs as he speaks to psychedelics analyst Tania Gonsalves, Vice President, Equity Research at Canaccord Genuity about the emerging psychedelics industry and which companies are leading the way to unlocking potent new ways of treating mental illnesses. (Transcript)
About Generation ETFs
Brought to you by Horizons ETFs Management (Canada) Inc., this podcast is dedicated to the next generation of investing. In this series, Generation ETFs aims to educate and inspire advisors and investors by discussing market trends and investment strategies with leading experts in the industry.
The views/opinions expressed herein may not necessarily be the views of Horizons ETFs Management (Canada) Inc. All comments, opinions and views expressed are of a general nature and should not be considered as investment advice to purchase or to sell mentioned securities. Before making any investment decision, please consult your investment advisor or advisors.
Certain statements may constitute a forward-looking statement, including those identified by the expression “expect” and similar expressions (including grammatical variations thereof). The forward-looking statements are not historical facts but reflect the speaker’s current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. These and other factors should be considered carefully and listeners should not place undue reliance on such forward-looking statements. These forward-looking statements are made as of the date hereof and the speakers do not undertake to update any forward-looking statement that is contained herein, whether as a result of new information, future events or otherwise, unless required by applicable law.
The Horizons Psychedelic Stock Index ETF (PSYK), through the ownership of life science companies in the psychedelic industry, may also have some exposure to the legal marijuana market in Canada, and the hemp industry and/or marijuana industry in certain U.S. states that have legalized marijuana for therapeutic or adult-use, which is currently illegal under U.S. federal law. However, the ETF will not be directly engaged in the manufacture, importation, possession, use, sale or distribution of hemp or marijuana in either Canada or the U.S. Please read the full risk disclosure in the prospectus before investing.
There are risks associated with this product. PSYK is expected to invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S. federal law, despite this prohibition, a limited number of states have either sought to decriminalize or authorize the medical use of certain psychedelic drugs and substances in limited circumstances. Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. Psychedelic drugs and substances in Canada are primarily regulated under the Controlled Drugs and Substances Act (the “CDSA”), the Food and Drug Act and the regulations promulgated thereunder. The medical use of certain psychedelic drugs and substances remain illegal under Canadian federal law unless discretionary exemptions are granted under the CDSA, while a limited number of other drugs and substances may be prescribed by a health care practitioner to patients under their care. Adult recreational use of psychedelic drugs and substances remains generally prohibited under the CDSA. Commercial activities involving psychedelic drugs and substances are permitted in Canada by parties who hold the required federal regulatory approvals and licences; however, distribution and sales opportunities for psychedelic drugs and substances are heavily restricted at this time. PSYK will passively invest in companies engaged in legal activities involving psychedelic drugs and substances in Canada and the U.S. where applicable laws permit such activities. PSYK will not be directly engaged in the manufacture, importation, possession, use, sale or distribution of psychedelic drugs or substances in either Canada or the U.S.